Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, was featured in the latest episode of the BioMedWire Podcast, which is part of a sustained effort by IBN (Investor Brand Network) to provide specialized content distribution via widespread syndication channels. During the episode, Clene CEO and president Rob Etherington talks with IBN’s Carmel Fisher about the company’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”).
“Clene Inc. is focused entirely on improving mitochondrial health and protecting neuron function,” said Clene CEO and president Rob Etherington in the press release. “We’re pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases. . . . Our drug enables the energetic capacity that those muscles require to function and, in the case of ALS, enables the main systems, primarily breathing, to be muscularly sustained so patients potentially have increased rates of survival, as our data suggests.”
To view the podcast, visit https://ibn.fm/a7e9u
To view the full press release, visit https://ibn.fm/KGwBG
About Clene Inc.
Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]